CSE:WBIO - Post Discussion
Post by
etcetera on Apr 29, 2020 9:50am
WPD receives approval for Annamycin dose escalation
2020-04-29 07:33 ET - News Release
Mr. Mariusz Olejniczak reports
WPD PHARMACEUTICAL'S ANNAMYCIN DRUG APPROVED FOR ACCELERATED EUROPEAN CLINICAL TRIAL
Through its licence partner, Moleculin Biotech Inc., WPD Pharmaceuticals Inc. has been authorized by the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, known as URPL, to accelerate the phase 1 dose escalation portion of its clinical trial of Annamycin for the treatment of acute myeloid leukemia (AML).
https://www.stockwatch.com/News/Item?bid=Z-C%3aWBIO-2897150&symbol=WBIO®ion=C
Be the first to comment on this post